ES2194265T3 - Derivados de piperidino 4-carboxamida y su utilizacion como antagonistas de la neuroquinina. - Google Patents

Derivados de piperidino 4-carboxamida y su utilizacion como antagonistas de la neuroquinina.

Info

Publication number
ES2194265T3
ES2194265T3 ES98119993T ES98119993T ES2194265T3 ES 2194265 T3 ES2194265 T3 ES 2194265T3 ES 98119993 T ES98119993 T ES 98119993T ES 98119993 T ES98119993 T ES 98119993T ES 2194265 T3 ES2194265 T3 ES 2194265T3
Authority
ES
Spain
Prior art keywords
derivatives
carboxamide
neuroquinine
new
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98119993T
Other languages
English (en)
Inventor
Scott Carson Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939314783A external-priority patent/GB9314783D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2194265T3 publication Critical patent/ES2194265T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS DE LA CARBOXAMIDA DE FORMULA I, QUE SE EXPONE A CONTINUACION, QUE ANTAGONIZAN LAS ACCIONES FARMACOLOGICAS DE UNA DE LAS TAQUIQUININAS NEUROPEPTIDICAS ENDOGENOS EN EL RECEPTOR DE LA NEUROQUININA 2 (NK2), HACIENDOLOS UTILES SIEMPRE QUE SE DESEA DICHO ANTAGONISMO, POR EJEMPLO, EN EL TRATAMIENTO DEL ASMA Y CUADROS SIMILARES. LA INVENCION PROPORCIONA ASI MISMO COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS NUEVOS DERIVADOS DE CARBOXAMIDA PARA USO EN DICHO TRATAMIENTO, LOS PROCEDIMIENTOS PARA SU USO Y LOS PROCESOS E INTERMEDIOS PARA LA FABRICACION DE LOS NUEVOS DERIVADOS DE LA CARBOXAMIDA.
ES98119993T 1992-11-03 1993-11-01 Derivados de piperidino 4-carboxamida y su utilizacion como antagonistas de la neuroquinina. Expired - Lifetime ES2194265T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97114192A 1992-11-03 1992-11-03
GB939314783A GB9314783D0 (en) 1993-07-16 1993-07-16 Carboxamide derivatives

Publications (1)

Publication Number Publication Date
ES2194265T3 true ES2194265T3 (es) 2003-11-16

Family

ID=26303251

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98119993T Expired - Lifetime ES2194265T3 (es) 1992-11-03 1993-11-01 Derivados de piperidino 4-carboxamida y su utilizacion como antagonistas de la neuroquinina.
ES93924135T Expired - Lifetime ES2134859T3 (es) 1992-11-03 1993-11-01 Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES93924135T Expired - Lifetime ES2134859T3 (es) 1992-11-03 1993-11-01 Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina.

Country Status (11)

Country Link
US (3) US5576333A (es)
EP (2) EP0897913B1 (es)
JP (1) JP3534759B2 (es)
CN (1) CN1094723A (es)
AU (1) AU5374294A (es)
DE (2) DE69332898T2 (es)
ES (2) ES2194265T3 (es)
GB (1) GB9321557D0 (es)
IL (1) IL107377A0 (es)
WO (1) WO1994010146A1 (es)
ZW (1) ZW13893A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
GB9325074D0 (en) * 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717802B1 (fr) * 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
GB9408872D0 (en) * 1994-05-03 1994-06-22 Zeneca Ltd Heterocyclic compounds
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
FR2725986B1 (fr) * 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) * 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
TW449590B (en) * 1995-04-14 2001-08-11 Boehringer Ingelheim Kg New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
US6413959B1 (en) 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
GB9508786D0 (en) 1995-04-29 1995-06-21 Zeneca Ltd Substituted heterocycles
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
GB9521781D0 (en) * 1995-10-24 1996-01-03 Merck Sharp & Dohme Therapeutic agents
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5948681A (en) * 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
JP2001508798A (ja) * 1997-01-21 2001-07-03 メルク エンド カンパニー インコーポレーテッド ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) * 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CA2309558C (en) * 1997-11-21 2005-05-03 Schering Corporation Substituted oximes as neurokinin antagonists
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6063926A (en) * 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
AR021968A1 (es) * 1998-12-23 2002-09-04 Schering Corp Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
SE0103795D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of överactive bladder
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8395020B2 (en) * 2006-08-31 2013-03-12 Monsanto Technology Llc Methods for rapidly transforming monocots
BRPI0815658A2 (pt) * 2007-08-07 2015-02-18 Hoffmann La Roche Aril-éter pirrolidina como antagonistas do receptor nk3
AU2008290634B2 (en) * 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
KR101174980B1 (ko) * 2007-09-14 2012-08-17 에프. 호프만-라 로슈 아게 Ｎｋ３ 수용체 길항제로서의 피페리딘 유도체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3381012A (en) * 1961-08-08 1968-04-30 Sterling Drug Inc Primary, secondary, and tertiary-(1-piperidyl)-lower-alkylamines
GB1538543A (en) * 1976-06-23 1979-01-24 Wyeth John & Brother Ltd N-aminoalkyl piperidine derivatives
US4167574A (en) * 1978-03-13 1979-09-11 Janssen Pharmaceutica, N.V. N-phenyl-N-(4-piperidinyl)amides
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2688219B1 (fr) * 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles

Also Published As

Publication number Publication date
DE69326160T2 (de) 1999-12-09
JPH08502511A (ja) 1996-03-19
EP0667858A1 (en) 1995-08-23
IL107377A0 (en) 1994-01-25
JP3534759B2 (ja) 2004-06-07
US5576333A (en) 1996-11-19
CN1094723A (zh) 1994-11-09
EP0897913A1 (en) 1999-02-24
DE69326160D1 (de) 1999-09-30
WO1994010146A1 (en) 1994-05-11
ZW13893A1 (en) 1994-07-27
US5559132A (en) 1996-09-24
ES2134859T3 (es) 1999-10-16
EP0667858B1 (en) 1999-08-25
EP0897913B1 (en) 2003-04-16
DE69332898D1 (de) 2003-05-22
GB9321557D0 (en) 1993-12-08
DE69332898T2 (de) 2004-01-15
AU5374294A (en) 1994-05-24
US5559131A (en) 1996-09-24

Similar Documents

Publication Publication Date Title
ES2135543T3 (es) Piperidinas (4-aril-sustituidas) como antagonistas de los receptores de neuroquininas.
ES2134859T3 (es) Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina.
ES2131106T3 (es) Compuestos de benzotiazepina hipolipidemicos.
AR032471A1 (es) Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter
CL2022002579A1 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
CR7069A (es) Derivados de pirazol para el tratamiento de vih
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
GT199900008A (es) Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1
ES2192264T3 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.
ES2113127T3 (es) Derivado de androstenona.
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
ES2127524T3 (es) Derivados de benzamida como antagonistas de vasopresina.
CR6859A (es) Compuestos de 1,4-dihidropiridina como antagonista de bradicinina
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
ES2067874T3 (es) Derivados de acetamida.
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
PY0225353A (es) Derivados del 3-azabiciclo [3.1.0] hexano
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
AR033659A1 (es) El compuesto 2-(3,5-bis -trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida), su uso, un procedimiento para prepararlo y un medicamento que lo contiene
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
ES2188801T3 (es) 4-(1h-bencimidazol-2-yl-amino) piperidinas sustituidas utiles para el tratamiento de enfermedades alergicas.
ES2115220T3 (es) Nuevo uso de compuestos bis-heterociclicos como agentes antiinflamatorios y composiciones farmaceuticas de los mismos.